{"entity":{"id":"nct07787520","kind":"trial","name":"A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of LAE118 run by Laekna Limited, not yet recruiting.","summary":"A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors is a phase 1 interventional study registered as NCT07787520 by Laekna Limited, with 150 participants planned, started 2026-08, primary completion expected 2029-03. Conditions recorded: Patients With Advanced Solid Tumors. Interventions recorded: LAE118, Fulvestrant, Palbociclib.","status":"planned","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT07787520","url":"https://clinicaltrials.gov/study/NCT07787520"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lae118"],"companies":["laekna-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07787520","phase":"1","setting":"A Phase I, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of LAE118 as Monotherapy and in Combination With Other Antitumor Agents in Patients With Advanced Solid Tumors","sponsor":"Laekna Limited","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07787520/","neighbours":{"drug":[{"id":"lae118","kind":"drug","name":"LAE118","route":"/drugs/lae118/"}],"company":[{"id":"laekna-therapeutics","kind":"company","name":"Laekna Therapeutics","route":"/companies/laekna-therapeutics/"}]}}